Inflammatory bowel disease in Africa: what is the current state of knowledge?

Phoebe Hodgesa,* and Paul Kellya,b

aBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK;
bTropical Gastroenterology and Nutrition Group, University of Zambia School of Medicine, University Teaching Hospital Nationalist Road, Lusaka, Zambia

*Corresponding author: Tel: +44 20 7882 7205; E-mail: p.hodges@qmul.ac.uk

Received 31 October 2019; revised 16 December 2019; editorial decision 15 January 2020; accepted 17 January 2020

Inflammatory bowel disease (IBD) is increasingly recognized as a global disease in the twenty-first century; however, little is known about its epidemiology in Africa. We conducted a literature review in order to assess what is currently known on this subject, the results of which are reported here. Based on available observational studies, it appears that the incidence of IBD in Africa is rising, although comprehensive epidemiological data are lacking. This is likely due to multiple factors, including shifting trends in diet and exposure to environmental pathogens. Many challenges relating to IBD exist for healthcare systems in Africa, including the need for improved access to diagnostic facilities such as endoscopy and histopathology, and the potential economic burden of treatment. Intestinal TB also represents a significant confounding factor in the diagnosis of IBD in Africa.

Keywords: inflammatory bowel disease, inflammatory bowel diseases, ulcerative colitis, Crohn’s, epidemiology

Introduction

The inflammatory bowel diseases (IBDs) ulcerative colitis (UC) and Crohn’s disease are chronic inflammatory conditions of the intestine, the exact causes of which are unknown. Current thinking is that they are likely to be the result of dysregulation of the intestinal immune response to components of the gut microbiota in genetically susceptible individuals.1,2 This could be thought of as a loss of oral tolerance, which is the lack of an immune response to soluble antigens in the intestinal luminal stream. Although long thought of as diseases of the West, these diseases have emerged over the past decade as a global public health challenge.3–6 This is particularly striking in Asia, where the prevalence of UC in parts of eastern Asia has been shown to be as high as 57.3/100 000.3 An increasing number of case reports and series from Africa suggest that the incidence on this continent is also rising. However, there are few data pertaining to the prevalence of IBD outside of North African countries and South Africa.7–9

Methods

We searched MEDLINE via PubMed from initiation up to and including 8 September 2019 for all studies relating to UC, Crohn’s disease or IBD in Africa. The combination of terms and keywords used for this search was ‘inflammatory bowel disease OR ulcerative colitis OR Crohn’s disease AND Africa’. The search identified 395 articles, and two additional studies were identified from citations. The initial stage of the review consisted of screening abstracts and titles of search results, following which 150 articles reporting on aspects of epidemiology, pathophysiology, diagnostic techniques or treatment were identified for full-text review.

Early reports

In 1946, Kibaya10 described the first likely case of Crohn’s disease in Africa in a 36-year-old Rwandan herdsman presenting with chronic intestinal obstruction with symptoms of constipation, vomiting after eating and anorexia. He was found to have an ileocaecal mass, which was resected, and histopathology showed that the caecal wall was ulcerated and the submucosa was congested. However, there was no evidence of TB, syphilis or amoebiasis and the appearance ‘resemble[d] those seen in Crohn’s ileitis”.

Following this, Billinghurst and Welchman11 reported four cases of UC in Kampala, Uganda in 1966, with the diagnosis based on typical sigmoidoscopic or radiographic appearances,
failure to identify any infective cause and response to corticosteroids. There were further case reports in the 1960s and 1970s, largely from South Africa, but there were also reports of UC from Nigeria, Tanzania, Kenya, Senegal and Zimbabwe. Despite this, Walker reported in 1979 that the disease was extremely rare among the rural South African black population, although the prevalence of UC in the white population of South Africa was similar to that of Western countries. He postulated that changes in environmental factors such as diet, smoking, atmospheric pollution and ‘stresses linked with urbanization and rise in class’ were likely to account for this.

For many years the majority of publications on IBD came from South Africa. Some comparison of incidence in different ethnic groups was attempted, although it should be borne in mind that there was a wide disparity in access to healthcare between black and white South Africans. A report published in 1980 from Baragwanath Hospital, Johannesburg suggested that although UC remained rare in black populations, the incidence (or at least diagnostic frequency) appeared to be increasing. This was based on the observation that only 18 cases were reported in sub-Saharan Africa up to 1975, but over a period of 4 years following this, 13 cases had been reported at this single centre. Epidemiological studies of IBD patients diagnosed in Cape Town between 1975 and 1980 reported that UC was a more common diagnosis than Crohn’s, with 220 new cases of UC compared with 117 cases of Crohn’s. A total of 3% of the UC patients were black, compared with only 1% of the Crohn’s patients. From 1980 to 1984, the incidence of UC in the black population in Cape Town was calculated to be 0.3/100 000 per year, compared with 2.6/100 000 per year in the white population.

Interestingly, a separate study of UC in the Indian population of Durban, South Africa, between 1983 and 1987 reported an incidence of 2.7/100 000 per year, comparable to that of the white population of Cape Town around that time. A case series of the first 46 black South African patients to be treated for UC at Baragwanath Hospital reported that 34 of these patients were women (female:male ratio 28:1), 94% were from urban areas and the patients generally had higher levels of education (67% having attended high school as opposed to only 27% of the general Sowetan black population at this time) and were from ‘higher occupational categories’ (23% being from professional occupations compared with only 6% of the general Sowetan black population).

**Temporal trends**

The relative frequency of UC diagnosis when compared with Crohn’s in Johannesburg was borne out by reports from Cairo, where data from a cohort of IBD patients diagnosed between 1995 and 2009 reported that the ratio of UC to Crohn’s was 6:1. It was also noted that the frequency of diagnoses of both Crohn’s and UC increased markedly over the latter 5 y of the study, with 88 cases being diagnosed over this time period as compared with only 70 cases in the 10 y period leading up to this. The male:female ratio in this study was 1:1.15, whereas Crohn’s seemed to occur predominantly in males, with the ratio being 2.6:1.

This trend mirrors that originally noted in industrialized countries, where UC was initially more common but has now been overtaken by Crohn’s. For example, the reported prevalence of Crohn’s in North America reached 319/100 000 in Nova Scotia, Canada, as opposed to the highest prevalence for UC which was 286/100 000 in Olmsted County, MN, USA. It seems that this is already the case in areas of North Africa, with the prevalence of UC in Constantine, Algeria reported to be lower than that of Crohn’s (the highest estimate being 19/100 000 vs only 11/100 000 for UC). Similarly in Tunisia, where IBD incidence appears to be increasing, Crohn’s seems to be diagnosed with more frequency than UC, representing 55.5% of the 202 diagnoses of IBD that were made between 1991 and 2005. This represented a change from the first part of the study period (1991–1993), where UC was diagnosed more frequently before being overtaken by Crohn’s for the remainder of the study period.

**IBD in Africa in the twenty-first century**

Larger epidemiological studies relating to IBD in Africa are lacking. In a recent systematic review of population-based studies of IBD, only one study from the continent met the requirements for inclusion, and this was from Algeria, where 299 cases of IBD (180 Crohn’s, 100 UC and 19 unclassified) were registered at the University Hospital in Constantine between January 2003 and December 2007, giving an average annual incidence of 5.87/100 000 for Crohn’s and 3.29/100 000 for UC. In addition, this study reported that the incidence of UC had risen during the 5 y period of the study from 2.76/100 000 in 2003 to 5.12/100 000 in 2007.

In sub-Saharan Africa, the majority of data relating to IBD incidence come from South Africa, where patient cohorts are primarily white, Asian or of mixed-race descent. For example, a retrospective analysis of a cohort of IBD patients seen at the Groote Schuur Hospital in Cape Town between 2002 and 2009 identified 1388 IBD patients who had attended the clinic, with only 5% of these being black. These patients were predominantly female (63%) and the majority had Crohn’s (53%). A later study from Cape Town investigating the relationship between race and Crohn’s phenotype in patients seen at the Groote Schuur Hospital between September 2011 and January 2013 included 194 patients, only 7 (4%) of whom were black, with the majority (78%) being ‘Cape Coloured’ (a term applied to people of mixed genetic origin including Europe, Africa and the Indian Ocean littoral) and 18% being white. There was no significant difference in disease behaviour between the white and Cape Coloured patients at initial diagnosis; however, over the course of follow-up (median disease duration 16 y), significantly more Cape Coloured patients developed complicated disease as defined by stricturing, penetrating or perianal disease or disease requiring surgical intervention (60% vs 9%). Although black patients were excluded from statistical analysis due to their relatively small numbers, all of these patients either had complicated disease at the time of diagnosis or developed complicated disease during follow-up. Interestingly, a positive family history of IBD in a first-degree relative was much more common among white patients (14%) as compared with only 6% of the Cape Coloured patients. None of the black patients had a first-degree relative with IBD. Although these numbers are small, this might suggest that genetic predisposition in IBD may vary with ethnicity.
Table 1. Case numbers reported from sub-Saharan African countries excluding South Africa (a full list of references included in the table is available in Appendix 1)

| Country      | Total cases reported, n | Crohn’s, n | UC, n | Indeterminate, n | Reference                                                                 |
|--------------|-------------------------|------------|-------|-----------------|---------------------------------------------------------------------------|
| Burkina Faso | 4                       | 2          | 2     |                 | Bougouma et al. 2002                                                     |
| Cameroon     | 1                       | 1          | 0     |                 | Alegbeleye 2019                                                          |
| Côte d’Ivoire| 3                       | 1          | 2     |                 | Casanelli et al. 2004, Okon et al. 2012                                  |
| Ethiopia     | 13                      | 8          | 5     |                 | Kefenie et al. 1987, Mengesha et al. 1997, Mengesha and Tsega 1989       |
| Ghana        | 45                      | 4          | 24    | 17              | Awori et al. 1972, Ogutu et al. 1998, Steury and Templeton 1980           |
| Kenya        | 18                      | 2          | 16    |                 | Adi and Lloyd 2010, Akere et al. 2016, Alatise et al. 2012, Alese and Ibar 2008, Khwaja et al. 1982, Naish et al. 1970, Senbanja et al. 2012, Ukwenya et al. 2011 |
| Nigeria      | 26                      | 8          | 18    |                 | Clerinx et al. 1995, Kibayo 1946                                         |
| Rwanda       | 3                       | 1          | 2     |                 | Carayon et al. 1968, Derrien et al. 1970, Dio et al. 2014, Diop et al. 2014, Peghini et al. 1988, Peghini et al. 1990 |
| Senegal      | 12                      | 3          | 9     |                 | Jones et al. 1977, Spencer and Nhonoi 1972                              |
| Tanzania     | 4                       | 0          | 4     |                 | Agoda-Koussera et al. 2012                                               |
| Togo         | 1                       | 0          | 1     |                 | Billinghurst and Welchman 1966                                           |
| Uganda       | 4                       | 0          | 4     |                 | Jena 1980, Muguiri 1989, Sealey and Gelfand 1968, Stein and Levy 1982     |
| Zimbabwe     | 10                      | 0          | 10    |                 |                                                                           |
known association for this disease. A Tunisian case–control study investigating the significance of variants of this gene in Crohn’s showed that the variants previously shown to be associated with Crohn’s in other populations were not as frequent in the Tunisian patients, and in fact there was no significant difference in their frequency between cases and controls.35 Similarly, in a cohort of IBD patients in Morocco, which has a significantly heterogeneous population in terms of ethnic diversity, it was reported that there was no significant difference in the frequency of the three common Crohn’s-associated variants in NOD2 between patients and controls (although analysis was not stratified by ethnic group).36 The same was true for variants of IL23R and ATG16L1 (other established risk loci of Crohn’s) in another case–control study from the same group.37 In South Africa, where variants of NOD2 were investigated in a cohort of ‘South African coloured’ IBD patients, again no statistically significant differences between cases and population-matched controls were identified.38 In a case–control study in Algeria, the observed
frequency of NOD2 mutant alleles was similar to that reported in European populations and a higher proportion of Crohn’s patients were carriers of at least one mutant allele in any variant (18.6% Crohn’s patients vs 10.2% controls); however, this association did not reach statistical significance. The authors postulated that this may be due to the lack of exposure to environmental factors that are fundamental to the pathophysiology of the disease.\(^{39}\)

The reported non-association of NOD2 variations and the paucity of other apparent risk loci for Crohn’s in these populations may be a result of the small numbers involved in these studies. However, given the lack of associations of genome-wide significance found in a cohort of 1646 African American Crohn’s patients,\(^{33}\) it may also imply a genetic characteristic specific to populations in this region; perhaps that there is greater genetic heterogeneity underlying Crohn’s than in previously studied populations or that genetic susceptibility confers a lesser degree of risk.

**Environmental factors/exposome**

**Diet and the microbiome**

One early theory relating to the increase in incidence of IBD in line with the demographic transition relates to the change in diet from a traditional rural diet that included a high intake of fibre and complex carbohydrate to one characterized by a high intake of fat and a high proportion of energy from animal protein; the so-called nutrition transition.\(^{40,41}\) It is postulated that ‘super-efficient’ carbohydrate absorption may lead to a reduced concentration of the short-chain fatty acids (SCFAs) acetate, propionate and butyrate generated in the colon. These changes in diet, particularly a reduction in fibre and complex carbohydrate intake, may result in an increased risk for gastrointestinal diseases more common in industrialized societies, including adenomas and colorectal cancers, diverticular disease and UC.\(^{42,43}\)

Non-digestible carbohydrates (dietary fibre) cannot be absorbed in the small intestine and reach the colon where they are fermented by the resident microbiota, generating SCFAs. SCFAs trigger signalling cascades by inhibition of histone deacetylases and activation of G-protein-coupled receptors (GPCRs) in intestinal epithelial cells and immune cells. The importance of this SCFA–GPCR pathway in IBD has been demonstrated in animal models; for example, Gpr43 knockout mice have been shown to develop more severe inflammation and higher levels of tumour necrosis factor (TNF)-α and interleukin-17 than wild-type mice in dextran sulphate sodium (DSS)-induced colitis. Furthermore, although the severity of DSS-induced colitis is inversely proportional to the amount of fibre that had been fed to the mice, this is not the case in Gpr43 knockout mice, suggesting that the demonstrated effect of dietary fibre content as a protective factor in colitis is mediated through this SCFA–GPCR pathway.\(^{44}\) A study from North India showed that there were reduced concentrations of the SCFAs butyrate and acetate in faecal samples from patients with UC, resulting from depleted levels of butyrate-producing bacteria.\(^{45}\)

**Hygiene hypothesis**

It has been proposed that living in an urban area is itself a risk factor for IBD, with a recent prospective population-based study in Asia reporting that higher population density was associated with increased risk of both UC and Crohn’s, and that the increased incidence of IBD in China is positively associated with gross domestic product.\(^{46}\) This may be explained by the hygiene hypothesis: improved sanitation in wealthy urban areas means that people are not exposed to enteric pathogens in childhood that they would have otherwise encountered if living in a less sanitized, poorer rural environment and this increases the risk of inappropriate response of the mucosal immune system when presented with these pathogens in later life. A recent case–control study conducted in patients with Crohn’s in South Africa showed that having piped tap water or bottled water as the primary source of drinking water between the ages of 0 and 10 y was associated with the development of Crohn’s.\(^{47}\) A meta-analysis of studies conducted in Europe, North America and Asia has shown an inverse association between access to bathrooms or hot water and UC, although no association was found with Crohn’s. Interestingly, this association was only evident in non-white populations.\(^{48}\)

Another case–control study conducted in South Africa that lends credence to this hypothesis found that 61.6% of IBD patients reported childhood helminth exposure compared with 91.3% of non-IBD controls (p<0.001), suggesting that childhood helminth exposure may be a protective factor for IBD.\(^{49}\) Helminthic infection is known to be associated with chronic immune downregulation through its effect on regulatory T-cell activity and this has been shown to have significant implications for the natural history and treatment of certain infections, for example hepatitis C virus in the context of schistosomiasis, as well as for the efficacy of childhood vaccines.\(^{50-52}\) It is possible, however, that this immune dysregulation may also confer a protective effect from autoimmune disorders such as IBD and this hypothesis has led to the exploration of therapeutic applications of helminth infections in IBD.\(^{53}\)

**Helicobacter pylori**

An Egyptian cohort study of 30 patients newly diagnosed with UC at Tanta University Hospital, Tanta, Egypt proposes that there may be an association between Helicobacter pylori and UC, with 40% of these patients testing positive for H. pylori by Giemsa staining of colonoscopic biopsies and 56.6% testing positive by immunohistochemistry, which was significantly more than in the control group, where only 13.3% were positive by Giemsa and 10% by immunohistochemistry. Furthermore, it was noted that four of the control cases who tested positive for H. pylori also had histopathological features of UC despite not having colitis that was evident at endoscopy. Given that the prevalence of H. pylori in the general Egyptian population has been reported to be as high as 88%, as the authors point out, the prevalence in the control group is unlikely to be reflective of prevalence in general, making the significance of these findings unclear.\(^{54}\)

**IBD vs TB**

No review of IBD in Africa would be complete without also discussing TB. The challenge of differentiating between the diagnosis of Crohn’s and intestinal TB (ITB) is becoming increasingly relevant in areas of the world where the incidence of IBD.
is increasing in parallel with urbanization, as both are chronic granulomatous conditions with a predilection for the ileocecal valve. This was recognized in South Africa by Segal, who described the clinicopathological similarities between ITB and Crohn’s in an urban black population in 1984. In the retrospective study of IBD patients in Khartoum described above, 42% of the patients who were eventually diagnosed with Crohn’s had initially been diagnosed with and treated for ITB. We will not discuss in detail the endoscopic, histological and radiological techniques used for differentiation between the two conditions, as these have been summarized in a recent review. Staining intestinal biopsies remains an important part of investigation, especially where granulomata are present. Although the sensitivity of Ziehl–Neelsen staining for diagnosis of ITB is low (2.7–37.5%), it may reveal the presence of fungal organisms, as may periodic acid–Schiff staining, which in colonic biopsies can also be used to detect Entamoeba histolytica. These differentials are critical when approaching granulomatous intestinal diseases in tropical settings. Since formalin-fixed biopsies cannot be used for culture, it is vital that additional biopsies are collected for TB culture at index endoscopy.

As well as the diagnostic difficulties outlined above, TB also represents a challenge in terms of treatment of IBD, as immunosuppressive treatments used in IBD pose a risk of reactivation of latent TB; experience using these therapies is largely in the context of populations where TB prevalence is low. At present there is a TB epidemic, with TB being one of the top 10 causes of death worldwide and, at 567/100 000, South Africa has the second highest TB incidence in the world. Deetlefs et al. conducted a retrospective analysis of a cohort of IBD patients seen in the gastroenterology clinic at Groote Schuur Hospital in Cape Town from 2002 to 2009 and found that of 1388 patients who had attended the clinic, 72 (11.7%) had been diagnosed with TB either before or after being diagnosed with IBD. A total of 30 of these patients had developed TB after IBD diagnosis and 7 of these had been exposed to immunosuppressive treatment for IBD (either azathioprine or the anti-TNF agent infliximab) within the 6 months prior to their TB diagnosis.

ITB is still likely to be more common than Crohn’s in Africa, although comprehensive epidemiological data are lacking. The similar presenting symptoms of these two diseases, combined with a lack of awareness in both clinicians and patients, as well as limited access to diagnostic resources make this a genuine diagnostic challenge. An incorrect diagnosis may have disastrous consequences, as immunosuppressive agents can potentially be fatal if the correct diagnosis is ITB. In practice, where there is diagnostic doubt, a trial of anti-TB treatment prior to making a diagnosis of Crohn’s may still be necessary.

Conclusions and future areas for research

Available evidence suggests that the incidence of IBD in Africa is increasing and, if this follows the same epidemiological trends as in the West and Asia, this is likely to represent a significant public health challenge in the near future. Larger epidemiological studies and establishment of local and regional registries are
needed, and all of this will require greatly increased access to endoscopy and histology services. The most pressing research need is to establish data on prevalence, but improved services are also needed to aid with diagnostic challenges such as differentiation of IBD from ITP, as discussed above, and to assess response to treatment. This epidemiological transition may offer further insights into environmental risk factors that play a role in the pathophysiology of IBD.

Authors’ contributions: PH performed the literature search and interpreted the data. PH and PK wrote the manuscript and created the figures. Endoscopic images were contributed by PK.

Acknowledgements: PH was supported by a Clinical Research Fellowship from Barts Charity.

Funding: None.

Competing interests: None declared.

Ethical approval: Not required.

References

1 de Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13–27.
2 Xu X-R, Liu C-Q, Feng B-S, Liu Z-J. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20(12):3255–64.
3 Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78.
4 Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7.
5 Maloedeky NA, Soon JS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel disease with time, based on systematic review. Gastroenterology 2012;142(1):46–54 e42; quiz e30.
6 Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21(8):40.
7 Esmat S, El Nady M, Elfekki M, Elsherif Y, Naga M. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. World J Gastroenterol. 2014;20(3):814–21.
8 Hammada T, Lemdaoui M-C, Boutra F, Zoughailech D, Asseolah H. Aspects épidermologiques des maladies inflammatoires chroniques de l’intestin dans une population algérienne. J Afr Hépat-Gastroentérologie. 2011;5:293–302.
9 Archampong TN, Nkrumah KN. Inflammatory bowel disease in Accra: what new trends. West Afr J Med. 2013;32(1):40–4.
10 Kiboya AK. Possible case of Crohn’s disease in a Ruanda native. East Afr Med J. 1994;62:317–20.
11 Billinghurst JR, Welchman JM. Idiopathic ulcerative colitis in the African: a report of 4 cases. Br Med J. 1966;1(5481):211–3.
12 Naish JM, Batchvarov BD, Lawoyin VL. A case of ulcerative colitis and pyostomatitis vegetans in an African. Gut. 1970;11(1):38–40.
13 Spencer SS, Nhonoli AM. Ulcerative colitis in east Africans. A report of three cases. East Afr Med J. 1972;49(2):163–9.
14 Awori NW, Rees PH, Roy AD. Causes of chronic diarrhoea in Kenya and their relationship to ulcerative colitis. East Afr Med J. 1972;49(8):604–13.
15 Carayon A, Reville JJ, Colomar R, Piquard B. Ulcerohemorrhagic rectocolitis in 2 Africans. Bull Soc Med Afr Noire Lang Fr. 1968;13(3):484–9.
16 Derrien JP, Maydat L, Piquard B, Ducloux M, Carayon A. Ulcerohemorrhagic rectocolitis in Africans of the black race (6 cases). Bull Soc Med Afr Noire Lang Fr. 1970;15(2):282–8.
17 Sealey BJ, Gelfand M. Ulcerative colitis in an African. Cent Afr J Med. 1968;14:173–5.
18 Walker AR, Segal I. Epidemiology of noninfective intestinal diseases in various ethnic groups in South Africa. Isr J Med Sci. 1979;15(4):309–13.
19 Segal I, Tim LO, Hamilton DG, Walker AR. The rarity of ulcerative colitis in South African blacks. Ann J Gastroenterol. 1980;74(4):332–6.
20 Wright JP, Marks IN, Jameson C, Garisch JA, Burns DG, Kottler RE. Inflammatory bowel disease in Cape Town, 1975–1980. Part I. Ulcerative colitis. S Afr Med J. 1983;63(7):223–6.
21 Wright JP, Marks IN, Jameson C, Garisch JA, Burns DG, Kottler RE. Inflammatory bowel disease in Cape Town, 1975–1980. Part II. Crohn’s disease. S Afr Med J. 1983;63(7):226–9.
22 Wright JP, Foggatt J, O’Keefe EA, et al. The epidemiology of inflammatory bowel disease in Cape Town 1980–1984. S Afr Med J. 1986;70(1):10–15.
23 Rajput HJ, Seebaran AR, Desai Y. Ulcerative colitis in the Indian population of Durban. S Afr Med J. 1992;81:245–8.
24 Segal I. Ulcerative colitis in a developing country of Africa: the Baragwanath experience of the first 46 patients. Int J Colorect Dis. 1988;3:222–5.
25 Ouakka Khooua A, Gargouri D, Bibani N, Elouaihi H, Kochlef A, Khorat J. Epidemiological evolution of epidemiology of the inflammatory bowel disease hospitals in a hospital of Tunisia. Tunis Med. 2013;91(1):70–3.
26 Deetlefs E, Epstein D, Watermeyer GA, Seggie RM, Thomson SR. Tuberculosis in an inflammatory bowel disease cohort from South Africa. S Afr Med J. 2012;102(10):802–4.
27 Basson A, Swart R, Jordaan E, Mazini M, Watermeyer G. The association between race and Crohn’s disease phenotype in the Western Cape population of South Africa, defined by the Montreal Classification System. PLoS One. 2014;9(4):e104859.
28 Ukwenyia AT, Ahmed A, Odigie VI, Mohammed M. Inflammatory bowel disease in Nigeria: still a rare diagnosis? Ann Afr Med. 2011; 10(2):175–9.
29 Ekwunife CN, Nweke IG, Achusi IB, Ekwunife CU. Ulcerative colitis prone to delayed diagnosis in a Nigerian population: case series. Ann Med Health Sci Res. 2015;5(4):311–3.
30 Akere A, Oke TO, Otegbayo JA. Colonoscopy at a tertiary healthcare facility in Southwest Nigeria: spectrum of indications and colonic abnormalities. Ann Afr Med. 2016;15(3):109–13.
31 Khalifa SE, Mudawi HMY, Fedali SS. Presentation and management outcome of inflammatory bowel disease in Sudan. Trop Gastroenterol. 2005;26:194–6.
32 McGovern DPB, Gardet A, Kortvost L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42(4):332–7.
33 Brant SR, et al. Genome-wide association study identifies African-specific susceptibility loci in African Americans with inflammatory bowel disease. Gastroenterology 2017;152:e2:206–17.
34 Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599–603.
35 Zouiten-Mekki L, Zaouali H, Boubaker J, et al. CARD15/NOD2 in a Tunisian population with Crohn’s disease. Dig Dis Sci. 2005;50:1309–13.
36 Segal I, Tim LO, Hamilton DG, Walker AR. The rarity of ulcerative colitis in South African blacks. Ann J Gastroenterol. 1980;74(4):332–6.
37 Serbat N, Badre W, Diakite B, Nadifi S. NOD2/CARD15 gene influences disease behaviour but not IBD susceptibility in a Moroccan population. Turk J Gastroenterol. 2014;25(Suppl 1):122–8.
38 Serbat N, Senhaji N, Diakite B, Badre W, Nadifi S. IL23R and ATG16L1 variants in Moroccan patients with inflammatory bowel disease. BMC Res Notes 2014;7:570.
Appendix 1

Adi AJ, Lloyd GJ. Crohn’s disease: a case report. Niger Q J Hosp Med. 201;20:46–8.

Agoda-Koussema LN, Anoukoum T, Djibril AM et al. [Ulcerative colitis: a case in Togo]. Med Sante Trop. 2012;22:79–81.

Akere A, Oke TO, Otegbayo JA. Colonoscopy at a tertiary healthcare facility in southwest Nigeria: spectrum of indications and colonic abnormalities. Ann Afr Med. 2016;15:109–13.

Alatise OI, Otegbayo JA, Nwosu MN, et al. Characteristics of inflammatory bowel disease in three tertiary health centers in southern Nigeria. West Afr J Med. 2012;31:28–33.

Alegebeye BJ. Crohn’s disease in a developing African mission hospital: a case report. J Med Case Rep. 2019;13:80.

Alse CE, Ibrar DO. Pyoderma gangrenosum and ulcerative colitis in the tropics. Rev Soc Bras Med Trop. 2008;41:664–7.

Archampong TN, Nkrumah KN. Inflammatory bowel disease in Accra: what new trends. West Afr J Med. 2013;32:40–4.

Awori NW, Rees PH, Ray AD. Causes of chronic diarrhoea in Kenya and their relationship to ulcerative colitis. East Afr Med J. 1972;49:604–13.

Billinghurst JR, Welchman JM. Idiopathic ulcerative colitis in the African: a report of 4 cases. Br Med J. 1966;1:211–3.

Bougouma A, Drabo YJ, Serme AK et al. [Analysis of the results of 1221 colonoscopies in the hospitals of Burkina Faso, 1994–1997]. Bull Soc Pathol Exot. 2002;95:50–2.

Carayon A, Reville JJ, Colamar R, Piquard B. [Ulcerohemorrhagic rectocolitis in 2 Africans]. Bull Soc Med Afr Noire Lang Fr. 1968;13:484–9.

Casaneli JM, et al. [Crohn’s disease: first report in Côte-d’Ivoire]. Med Trop Rev Corps Sante Colon. 2004;6:384–6.

Clerinx J, Bogarts J, Taelman H, et al. Chronic diarrhea among adults in Kigali, Rwanda: association with bacterial enteropathogens, rectocolonic inflammation, and human immunodeficiency virus infection. Clin Infect Dis. 1995;21:1282–4.

Derrien JP, Maydat L, Piquard B, Carayon A. [Ulcerohemorrhagic rectocolitis in Africans of the black race (6 cases)]. Bull Soc Med Afr Noire Lang Fr. 1970;15:282–8.

Dia D, et al. [Severe acute colitis: two fatal cases in Dakar]. Med Sante Trop. 2014;24:438–40.

Diop MG, et al. [Tuberculoid leprosy revealed by active ulcerative colitis: a case report]. Med Sante Trop. 2014;24:333–5.

Jena GP. Idiopathic ulcerative colitis in a Zimbabwean African patient. S Afr J Surg. 1980;18:157–9.

Jones ME, Bewes PC, Hulme-Moir I. Ulcerative colitis in an African: a fatal case in Tanzania. East Afr Med J. 1977;54:670–3.

Kefenin H, Negesse Y, Oljo G, Gebre-Sellassie L. Crohn’s disease in an Ethiopian. Ethiop Med J. 1987;25:161–4.

Khwaja MS, Thakur PS, Lawrie JH. Crohn’s disease in a Nigerian. Arch Surg. 1982;117:957–9.

Kibaya AK. Possible case of Crohn’s disease in a Ruanda native. East Afr Med J. 1946;23:317–20.

Mengesha B, Johnson O, Taye M, Gemetchu T. Crohn’s disease: report of seven cases from Ethiopia. East Afr Med J. 1997;74:397–9.

Mengesha B, Tsegay E. Idiopathic ulcerative colitis among Ethiopian patients with chronic diarrhoea. Ethiop Med J. 1989;27:63–72.

Muguti GI. Ulcerative proctocolitis in black Zimbabweans. Cent Afr J Med. 1989;35:300–3.

Naish JM, Batchvarov BD, Lawoyin VL. A case of ulcerative colitis and pyostomatitis vegetans in an African. Gut. 1970;11:38–40.
Ogutu EO, Okoth FA, Lule GN. Colonoscopic findings in Kenyan African patients. East Afr Med J. 1998;75:540–3.
Okon JB, Assi C, Diakité M, et al. [Pediatric colonoscopy at the University Hospital of Cocody (Ivory Coast)]. Med Sante Trop. 2012;22:222–3.
Peghini M, Barabe P, Morcillo R, et al. [Crohn's disease. Apropos of 2 recent cases collected at the Dakar Central Hospital]. Dakar Med. 1990;35:52–4.
Peghini M, Barabe P, Veillard JM, et al. [Gastric Crohn's disease (1st African case seen at the Hôpital Principal in Dakar)]. Dakar Med. 1988;33:107–10.
Sealey BJ, Gelfand M. Ulcerative colitis in an African. Cent Afr J Med. 1968;14:173–5.
Senbanjo IO, Oshikoya KA, Onyekwere CA, Abdulkareem FB, Njokanma OF. Ulcerative colitis in a Nigerian girl: a case report. BMC Res Notes. 2012;5:564.
Spencer SS, Nhonoli AM. Ulcerative colitis in East Africans. A report of three cases. East Afr Med J. 1972;49:163–9.
Stein CM, Levy LM. Ulcerative colitis in Zimbabwe. Cent Afr J Med. 1982;28:263–5.
Steury EM, Templeton AC. Crohn's disease in Africa. A case report and review. Trop Geogr Med. 1980;32:172–3.
Ukwenya AY, Ahmed A, Odigie VI, Mohammed A. Inflammatory bowel disease in Nigerians: still a rare diagnosis? Ann Afr Med. 2011;10:175–9.